minoxidil (15 months) and pyrilutamide (46 days) results.
    9/15/2024

    From the encyclopedia
    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    Pyrilutamide →

    highly targeted anti-androgen that might have minimal systemic effects

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💧 Minoxidil (topical) 15 months
    💧 Pyrilutamide (topical) 46 days
    the tone is 😀 positive with desired results.

    Other terms

    OP used minoxidil for 15 months and pyrilutamide for 46 days, achieving desired results without side effects. Users discussed alternatives like dutasteride and finasteride, with concerns about side effects like erectile dysfunction.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results
      Androgenetic Alopecia: Therapy Update

      research Androgenetic Alopecia: Therapy Update

      May 2023 in “Drugs”
      This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
      The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis

      research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis

      March 2025 in “Medicine”
      This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.
      Updates in Treatment for Androgenetic Alopecia

      research Updates in Treatment for Androgenetic Alopecia

      January 2025 in “Annals of Dermatology”
      This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.